Manuel R. Teixeira

List of Publications by Year in Descending Order

317 papers	12,186 citations	57 h-index	94 g-index
339 ext. papers	14,649 ext. citations	8.2 avg, IF	5.33 L-index

#	Paper	IF	Citations
317	KRAS and NRAS mutational analysis in plasma ctDNA from patients with metastatic colorectal cancer by real-time PCR and digital PCR.. *International Journal of Colorectal Disease*, **2022**, 37, 895	3	0
316	A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study. *Lancet Oncology, The*, **2021**, 22, 1618-1631	21.7	10
315	The role of TP53 pathogenic variants in early-onset HER2-positive breast cancer. *Familial Cancer*, **2021**, 20, 173-180	3	1
314	Case Report: Pheochromocytoma and Synchronous Neuroblastoma in a Family With Hereditary Pheochromocytoma Associated With a MAX Deleterious Variant. *Frontiers in Endocrinology*, **2021**, 12, 609263	5.7	1
313	KLK3 SNP-SNP interactions for prediction of prostate cancer aggressiveness. *Scientific Reports*, **2021**, 11, 9264	4.9	3
312	When to Stop TKIs in Patients with Chronic Myeloid Leukemia and How to Follow Them Subsequently. *Current Treatment Options in Oncology*, **2021**, 22, 49	5.4	
311	The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. *Genetics in Medicine*, **2021**, 23, 1726-1737	8.1	2
310	Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. *Nature Genetics*, **2021**, 53, 65-75	36.3	62
309	Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer. *Prostate Cancer and Prostatic Diseases*, **2021**, 24, 532-541	6.2	3
308	Polygenic hazard score is associated with prostate cancer in multi-ethnic populations. *Nature Communications*, **2021**, 12, 1236	17.4	14
307	Multi-Gene Panel Testing in Gastroenterology: Are We Ready for the Results?. *GE Portuguese Journal of Gastroenterology*, **2021**, 28, 403-409	1.1	0
306	Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores. *Journal of the National Cancer Institute*, **2021**,	9.7	3
305	Rare Germline Variants in ATM Predispose to Prostate Cancer: A PRACTICAL Consortium Study. *European Urology Oncology*, **2021**, 4, 570-579	6.7	12
304	Next Generation Sequencing of Tumor and Matched Plasma Samples: Identification of Somatic Variants in ctDNA From Ovarian Cancer Patients. *Frontiers in Oncology*, **2021**, 11, 754094	5.3	1
303	Identification of as a Novel Candidate Susceptibility Gene for Familial Nonmedullary Thyroid Cancer. *Thyroid*, **2021**, 31, 1366-1375	6.2	1
302	The Variant C.349A>G Is Associated with Prostate Cancer Risk and Carriers Share a Common Ancestor. *Cancers*, **2020**, 12,	6.6	4
301	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. *Nature Genetics*, **2020**, 52, 572-581	36.3	76

300	The effect of sample size on polygenic hazard models for prostate cancer. *European Journal of Human Genetics*, **2020**, 28, 1467-1475	5.3	5
299	Surveillance of succinate dehydrogenase gene mutation carriers: Insights from a nationwide cohort. *Clinical Endocrinology*, **2020**, 92, 545-553	3.4	5
298	A Genetic Risk Score to Personalize Prostate Cancer Screening, Applied to Population Data. *Cancer Epidemiology Biomarkers and Prevention*, **2020**, 29, 1731-1738	4	14
297	Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). *JAMA Oncology*, **2020**, 6, 1218-1230	13.4	25
296	Transcriptome-wide association study of breast cancer risk by estrogen-receptor status. *Genetic Epidemiology*, **2020**, 44, 442-468	2.6	9
295	A network analysis to identify mediators of germline-driven differences in breast cancer prognosis. *Nature Communications*, **2020**, 11, 312	17.4	20
294	The Spectrum of Protein Truncating Variants in European Breast Cancer Cases. *Cancers*, **2020**, 12,	6.6	7
293	Association of Genomic Domains in and with Prostate Cancer Risk and Aggressiveness. *Cancer Research*, **2020**, 80, 624-638	10.1	22
292	Myeloid Disease with the CSF3R T618I Mutation after CLL. *Case Reports in Hematology*, **2020**, 2020, 6670965	0.7	
291	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. *Nature Genetics*, **2020**, 52, 56-73	36.3	56
290	Pathogenicity reclassification of two BRCA1/BRCA2 exonic duplications after identification of genomic breakpoints and tandem orientation. *Cancer Genetics*, **2020**, 248-249, 18-24	2.3	
289	Haplotype analysis of the internationally distributed BRCA1 c.3331_3334delCAAG founder mutation reveals a common ancestral origin in Iberia. *Breast Cancer Research*, **2020**, 22, 108	8.3	0
288	Gene Panel Tumor Testing in Ovarian Cancer Patients Significantly Increases the Yield of Clinically Actionable Germline Variants beyond /. *Cancers*, **2020**, 12,	6.6	2
287	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. *Genetics in Medicine*, **2020**, 22, 1653-1666	8.1	34
286	Hereditary Predisposition to Prostate Cancer: From Genetics to Clinical Implications. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	16
285	An integrative multi-omics analysis to identify candidate DNA methylation biomarkers related to prostate cancer risk. *Nature Communications*, **2020**, 11, 3905	17.4	12
284	Tumor Testing for Somatic and Germline / Variants in Ovarian Cancer Patients in the Context of Strong Founder Effects. *Frontiers in Oncology*, **2020**, 10, 1318	5.3	3
283	Association of germline variation with the survival of women with pathogenic variants and breast cancer. *Npj Breast Cancer*, **2020**, 6, 44	7.8	3

282	Widening the spectrum of Lynch syndrome: first report of testicular seminoma attributable to MSH2 loss. *Histopathology*, **2020**, 76, 486-489	7.3	4
281	Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. *European Urology*, **2019**, 76, 831-842	10.2	78
280	Shared heritability and functional enrichment across six solid cancers. *Nature Communications*, **2019** , 10, 431	17.4	45
279	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. *British Journal of Cancer*, **2019**, 121, 180-192	8.7	13
278	Negative MR chronic myeloid leukaemia and its possible implications for treatment-free remission. *British Journal of Haematology*, **2019**, 186, e181-e184	4.5	1
277	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. *Nature Communications*, **2019**, 10, 1741	17.4	47
276	The nonsense mutation MSH2 c.2152C>T shows a founder effect in Portuguese Lynch syndrome families. *Genes Chromosomes and Cancer*, **2019**, 58, 657-664	5	1
275	Genome-wide association study of germline variants and breast cancer-specific mortality. *British Journal of Cancer*, **2019**, 120, 647-657	8.7	28
274	The :p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. *Npj Breast Cancer*, **2019**, 5, 38	7.8	12
273	Genetic counselling and testing of susceptibility genes for therapeutic decision-making in breast cancer-an European consensus statement and expert recommendations. *European Journal of Cancer*, **2019**, 106, 54-60	7.5	13
272	Circulating Metabolic Biomarkers of Screen-Detected Prostate Cancer in the ProtecT Study. *Cancer Epidemiology Biomarkers and Prevention*, **2019**, 28, 208-216	4	9
271	Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. *Journal of the National Cancer Institute*, **2019**, 111, 350-364	9.7	22
270	Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. *Human Mutation*, **2018**, 39, 593-620	4.7	138
269	Contribution of MLH1 constitutional methylation for Lynch syndrome diagnosis in patients with tumor MLH1 downregulation. *Cancer Medicine*, **2018**, 7, 433-444	4.8	18
268	Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. *British Journal of Cancer*, **2018**, 118, 266-276	8.7	9
267	Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts. *BMJ, The*, **2018**, 360, j5757	5.9	85
266	Germline pathogenic variants in PALB2 and other cancer-predisposing genes in families with hereditary diffuse gastric cancer without CDH1 mutation: a whole-exome sequencing study. *The Lancet Gastroenterology and Hepatology*, **2018**, 3, 489-498	18.8	58
265	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. *Cancer Research*, **2018**, 78, 5419-5430	10.1	32

264	AA9int: SNP interaction pattern search using non-hierarchical additive model set. *Bioinformatics*, **2018**, 34, 4141-4150	7.2	3
263	Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. *Nature Genetics*, **2018**, 50, 928-936	36.3	340
262	Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. *Nature Communications*, **2018**, 9, 2256	17.4	57
261	Detection of microsatellite instability (MSI) in colorectal cancer samples with a novel set of highly sensitive markers by means of the Idylla MSI Test prototype.. *Journal of Clinical Oncology*, **2018**, 36, e15639-e15639	2.2	8
260	Full in-frame exon 3 skipping of confers high risk of breast and/or ovarian cancer. *Oncotarget*, **2018**, 9, 17334-17348	3.3	13
259	Genetic Testing and Clinical Management Practices for Variants in Non-BRCA1/2 Breast (and Breast/Ovarian) Cancer Susceptibility Genes: An International Survey by the Evidence-Based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) Clinical Working Group. *JCO Precision Oncology*, **2018**, 2,	3.6	12
258	Germline variation at 8q24 and prostate cancer risk in men of European ancestry. *Nature Communications*, **2018**, 9, 4616	17.4	30
257	Discontinuation of tyrosine kinase inhibitors in CML patients in real-world clinical practice at a single institution. *BMC Cancer*, **2018**, 18, 1245	4.8	11
256	Potential clinical applications of circulating cell-free DNA in ovarian cancer patients. *Expert Reviews in Molecular Medicine*, **2018**, 20, e6	6.7	13
255	Ponatinib induces a sustained deep molecular response in a chronic myeloid leukaemia patient with an early relapse with a T315I mutation following allogeneic hematopoietic stem cell transplantation: a case report. *BMC Cancer*, **2018**, 18, 1229	4.8	9
254	Screening and characterization of BRCA2 c.156_157insAlu in Brazil: Results from 1380 individuals from the South and Southeast. *Cancer Genetics*, **2018**, 228-229, 93-97	2.3	2
253	Hybrid oncocytic/chromophobe renal cell tumor: An integrated genetic and epigenetic characterization of a case. *Experimental and Molecular Pathology*, **2018**, 105, 352-356	4.4	2
252	Targeted next generation sequencing identifies functionally deleterious germline mutations in novel genes in early-onset/familial prostate cancer. *PLoS Genetics*, **2018**, 14, e1007355	6	34
251	Identification of somatic TERT promoter mutations in familial nonmedullary thyroid carcinomas. *Clinical Endocrinology*, **2017**, 87, 394-399	3.4	12
250	Ovarian metastasis from uveal melanoma with MLH1/PMS2 protein loss in a patient with germline MLH1 mutated Lynch syndrome: consequence or coincidence?. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2017**, 470, 347-352	5.1	8
249	Validation of a Next-Generation Sequencing Pipeline for the Molecular Diagnosis of Multiple Inherited Cancer Predisposing Syndromes. *Journal of Molecular Diagnostics*, **2017**, 19, 502-513	5.1	7
248	Bromodomain protein 4 discriminates tissue-specific super-enhancers containing disease-specific susceptibility loci in prostate and breast cancer. *BMC Genomics*, **2017**, 18, 270	4.5	22
247	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. *Nature Genetics*, **2017**, 49, 680-691	36.3	190

246	Germline Mutations in PALB2, BRCA1, and RAD51C, Which Regulate DNA Recombination Repair, in Patients With Gastric Cancer. *Gastroenterology*, **2017**, 152, 983-986.e6	13.3	69
245	POLE somatic mutations in advanced colorectal cancer. *Cancer Medicine*, **2017**, 6, 2966-2971	4.8	31
244	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. *Nature Genetics*, **2017**, 49, 1767-1778	36.3	186
243	Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. *Journal of Clinical Oncology*, **2017**, 35, 2240-2250	2.2	101
242	Height, selected genetic markers and prostate cancer risk: results from the PRACTICAL consortium. *British Journal of Cancer*, **2017**, 117, 734-743	8.7	5
241	Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibility. *Nature Communications*, **2017**, 8, 1892	17.4	24
240	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. *Breast Cancer Research and Treatment*, **2017**, 161, 117-134	4.4	15
239	Investigating the possible causal role of coffee consumption with prostate cancer risk and progression using Mendelian randomization analysis. *International Journal of Cancer*, **2017**, 140, 322-328	7.5	13
238	Performance of Lynch syndrome predictive models in quantifying the likelihood of germline mutations in patients with abnormal MLH1 immunoexpression. *Familial Cancer*, **2017**, 16, 73-81	3	1
237	Alcohol consumption and prostate cancer incidence and progression: A Mendelian randomisation study. *International Journal of Cancer*, **2017**, 140, 75-85	7.5	22
236	Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. *Journal of the National Cancer Institute*, **2017**, 109,	9.7	153
235	SNP interaction pattern identifier (SIPI): an intensive search for SNP-SNP interaction patterns. *Bioinformatics*, **2017**, 33, 822-833	7.2	8
234	Co-occurrence of nonsense mutations in MSH6 and MSH2 in Lynch syndrome families evidencing that not all truncating mutations are equal. *Journal of Human Genetics*, **2016**, 61, 151-6	4.3	4
233	The role of germline mutations in the BRCA1/2 and mismatch repair genes in men ascertained for early-onset and/or familial prostate cancer. *Familial Cancer*, **2016**, 15, 111-21	3	18
232	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. *Gynecologic Oncology*, **2016**, 141, 386-401	4.9	15
231	Implementation of next-generation sequencing for molecular diagnosis of hereditary breast and ovarian cancer highlights its genetic heterogeneity. *Breast Cancer Research and Treatment*, **2016**, 159, 245-56	4.4	20
230	Truncating and missense PPM1D mutations in early-onset and/or familial/hereditary prostate cancer patients. *Genes Chromosomes and Cancer*, **2016**, 55, 954-961	5	11
229	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. *Cancer Discovery*, **2016**, 6, 1052-67	24.4	104

228	Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. *Breast Cancer Research*, **2016**, 18, 112	8.3	25
227	Prostate cancer risk regions at 8q24 and 17q24 are differentially associated with somatic TMPRSS2:ERG fusion status. *Human Molecular Genetics*, **2016**, 25, 5490-5499	5.6	6
226	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. *Nature Communications*, **2016**, 7, 11375	17.4	64
225	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. *Nature Communications*, **2016**, 7, 12675	17.4	53
224	Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation. *Nature Communications*, **2016**, 7, 10979	17.4	37
223	Pubertal development and prostate cancer risk: Mendelian randomization study in a population-based cohort. *BMC Medicine*, **2016**, 14, 66	11.4	29
222	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. *Nature Genetics*, **2016**, 48, 374-86	36.3	93
221	Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array. *British Journal of Cancer*, **2016**, 114, 945-52	8.7	13
220	BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. *Journal of the National Cancer Institute*, **2016**, 108,	9.7	65
219	BRCA1 and BRCA2 rearrangements in Brazilian individuals with Hereditary Breast and Ovarian Cancer Syndrome. *Genetics and Molecular Biology*, **2016**, 39, 223-31	2	16
218	Lapatinib-capecitabine versus capecitabine alone as radiosensitizers in RAS wild-type resectable rectal cancer, an adaptive randomized phase II trial (LaRRC trial): study protocol for a randomized controlled trial. *Trials*, **2016**, 17, 459	2.8	2
217	Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. *PLoS ONE*, **2016**, 11, e0158801	3.7	7
216	Analysis of Founder Mutations in Rare Tumors Associated With Hereditary Breast/Ovarian Cancer Reveals a Novel Association of BRCA2 Mutations with Ampulla of Vater Carcinomas. *PLoS ONE*, **2016**, 11, e0161438	3.7	10
215	Oncogenic mechanisms of missense mutations in prostate carcinogenesis. *Oncoscience*, **2016**, 3, 288-296	0.8	7
214	NCOA2 is a candidate target gene of 8q gain associated with clinically aggressive prostate cancer. *Genes Chromosomes and Cancer*, **2016**, 55, 365-74	5	9
213	PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. *Journal of Medical Genetics*, **2016**, 53, 800-811	5.8	121
212	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. *Breast Cancer Research*, **2016**, 18, 64	8.3	25
211	Correspondence: SEMA4A variation and risk of colorectal cancer. *Nature Communications*, **2016**, 7, 10611	17.4	6

210	Cancer Prognosis Defined by the Combined Analysis of 8q, PTEN and ERG. *Translational Oncology*, **2016**, 9, 575-582	4.9	10
209	Pathologic Findings in Prophylactic and Nonprophylactic Hysterectomy Specimens of Patients With Lynch Syndrome. *American Journal of Surgical Pathology*, **2016**, 40, 1177-91	6.7	19
208	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. *Breast Cancer Research*, **2016**, 18, 15	8.3	58
207	Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas. *Blood*, **2016**, 127, 3026-34	2.2	126
206	Polyunsaturated fatty acids and prostate cancer risk: a Mendelian randomisation analysis from the PRACTICAL consortium. *British Journal of Cancer*, **2016**, 115, 624-31	8.7	21
205	Assessing the role of insulin-like growth factors and binding proteins in prostate cancer using Mendelian randomization: Genetic variants as instruments for circulating levels. *International Journal of Cancer*, **2016**, 139, 1520-33	7.5	18
204	Blood lipids and prostate cancer: a Mendelian randomization analysis. *Cancer Medicine*, **2016**, 5, 1125-36	4.8	45
203	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. *Nature Genetics*, **2015**, 47, 164-71	36.3	177
202	Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. *JAMA - Journal of the American Medical Association*, **2015**, 313, 1347-61	27.4	286
201	The effects of height and BMI on prostate cancer incidence and mortality: a Mendelian randomization study in 20,848 cases and 20,214 controls from the PRACTICAL consortium. *Cancer Causes and Control*, **2015**, 26, 1603-16	2.8	56
200	Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans. *Human Molecular Genetics*, **2015**, 24, 5589-602	5.6	54
199	Target gene mutational pattern in Lynch syndrome colorectal carcinomas according to tumour location and germline mutation. *British Journal of Cancer*, **2015**, 113, 686-92	8.7	26
198	Genome-wide association study of prostate cancer-specific survival. *Cancer Epidemiology Biomarkers and Prevention*, **2015**, 24, 1796-800	4	23
197	The role of targeted BRCA1/BRCA2 mutation analysis in hereditary breast/ovarian cancer families of Portuguese ancestry. *Clinical Genetics*, **2015**, 88, 41-8	4	18
196	Fine-mapping of the HNF1B multicancer locus identifies candidate variants that mediate endometrial cancer risk. *Human Molecular Genetics*, **2015**, 24, 1478-92	5.6	46
195	Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. *Cancer Epidemiology Biomarkers and Prevention*, **2015**, 24, 308-16	4	20
194	Identification of previously unrecognized FAP in children with Gardner fibroma. *European Journal of Human Genetics*, **2015**, 23, 715-8	5.3	9
193	Recurrent Coding Sequence Variation Explains Only A Small Fraction of the Genetic Architecture of Colorectal Cancer. *Scientific Reports*, **2015**, 5, 16286	4.9	21

192	Meta-analysis of genome-wide association studies identifies common susceptibility polymorphisms for colorectal and endometrial cancer near SH2B3 and TSHZ1. *Scientific Reports*, **2015**, 5, 17369	4.9	27
191	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. *Breast Cancer Research*, **2015**, 17, 61	8.3	16
190	Prediction of individual genetic risk to prostate cancer using a polygenic score. *Prostate*, **2015**, 75, 1467-74	4.2	43
189	Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers. *PLoS ONE*, **2015**, 10, e0120020	3.7	26
188	Identification of Two Novel HOXB13 Germline Mutations in Portuguese Prostate Cancer Patients. *PLoS ONE*, **2015**, 10, e0132728	3.7	31
187	Frequent alterations in cytoskeleton remodelling genes in primary and metastatic lung adenocarcinomas. *Nature Communications*, **2015**, 6, 10131	17.4	67
186	A Large-Scale Analysis of Genetic Variants within Putative miRNA Binding Sites in Prostate Cancer. *Cancer Discovery*, **2015**, 5, 368-79	24.4	41
185	Uncovering potential downstream targets of oncogenic GRPR overexpression in prostate carcinomas harboring ETS rearrangements. *Oncoscience*, **2015**, 2, 497-507	0.8	9
184	Specific and redundant activities of ETV1 and ETV4 in prostate cancer aggressiveness revealed by co-overexpression cellular contexts. *Oncotarget*, **2015**, 6, 5217-36	3.3	17
183	Constitutional and somatic rearrangement of chromosome 21 in acute lymphoblastic leukaemia. *Nature*, **2014**, 508, 98-102	50.4	192
182	Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study. *European Urology*, **2014**, 66, 489-99	10.2	156
181	Pathogenicity evaluation of BRCA1 and BRCA2 unclassified variants identified in Portuguese breast/ovarian cancer families. *Journal of Molecular Diagnostics*, **2014**, 16, 324-34	5.1	16
180	PNET with neuroendocrine differentiation of the lung: Report of an unusual entity. *International Journal of Surgical Pathology*, **2014**, 22, 427-33	1.2	7
179	The Brazilian founder mutation TP53 p.R337H is uncommon in Portuguese women diagnosed with breast cancer. *Breast Journal*, **2014**, 20, 534-6	1.2	5
178	Transcriptome instability as a molecular pan-cancer characteristic of carcinomas. *BMC Genomics*, **2014**, 15, 672	4.5	13
177	A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. *Nature Genetics*, **2014**, 46, 1103-9	36.3	331
176	Re: Role of the oxidative DNA damage repair gene OGG1 in colorectal tumorigenesis. *Journal of the National Cancer Institute*, **2014**, 106,	9.7	8
175	Gene amplification of the histone methyltransferase SETDB1 contributes to human lung tumorigenesis. *Oncogene*, **2014**, 33, 2807-13	9.2	94

174	Exome sequencing reveals novel mutation targets in diffuse large B-cell lymphomas derived from Chinese patients. *Blood*, **2014**, 124, 2544-53	2.2	82
173	Epigenetic regulation of EFEMP1 in prostate cancer: biological relevance and clinical potential. *Journal of Cellular and Molecular Medicine*, **2014**, 18, 2287-97	5.6	21
172	DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. *PLoS Genetics*, **2014**, 10, e1004256	6	33
171	Fine-mapping the HOXB region detects common variants tagging a rare coding allele: evidence for synthetic association in prostate cancer. *PLoS Genetics*, **2014**, 10, e1004129	6	30
170	After Angelina and the Supreme Court Decision, where do we go from here? BRCA gene testing in Rhode Island's Portuguese population. *American Journal of Medical Genetics, Part A*, **2014**, 164A, 557-8	2.5	
169	Familial vs sporadic papillary thyroid carcinoma: a matched-case comparative study showing similar clinical/prognostic behaviour. *European Journal of Endocrinology*, **2014**, 170, 321-7	6.5	38
168	Carcinoma of the thyroid with Ewing/PNET family tumor elements: a tumor of unknown histogenesis. *International Journal of Surgical Pathology*, **2014**, 22, 579-81	1.2	16
167	Carcinoma of the thyroid with ewing family tumor elements and favorable prognosis: report of a second case. *International Journal of Surgical Pathology*, **2014**, 22, 260-5	1.2	22
166	Immunohistochemical molecular phenotypes of gastric cancer based on SOX2 and CDX2 predict patient outcome. *BMC Cancer*, **2014**, 14, 753	4.8	26
165	Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. *Breast Cancer Research*, **2014**, 16, 3416	8.3	46
164	High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer. *BMC Cancer*, **2013**, 13, 169	4.8	36
163	POU1F1 is a novel fusion partner of NUP98 in acute myeloid leukemia with t(3;11)(p11;p15). *Molecular Cancer*, **2013**, 12, 5	42.1	9
162	Frequent copy number gains at 1q21 and 1q32 are associated with overexpression of the ETS transcription factors ETV3 and ELF3 in breast cancer irrespective of molecular subtypes. *Breast Cancer Research and Treatment*, **2013**, 138, 37-45	4.4	32
161	The MSH2 c.388_389del mutation shows a founder effect in Portuguese Lynch syndrome families. *Clinical Genetics*, **2013**, 84, 244-50	4	11
160	Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression. *Human Molecular Genetics*, **2013**, 22, 4239-4239	5.6	2
159	Novel 5' fusion partners of ETV1 and ETV4 in prostate cancer. *Neoplasia*, **2013**, 15, 720-6	6.4	27
158	The MLL recombinome of acute leukemias in 2013. *Leukemia*, **2013**, 27, 2165-76	10.7	326
157	Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. *Nature Genetics*, **2013**, 45, 385-91, 391e1-2	36.3	413

156	DNA repair genes are selectively mutated in diffuse large B cell lymphomas. *Journal of Experimental Medicine*, **2013**, 210, 1729-42	16.6	74
155	Common fusion transcripts identified in colorectal cancer cell lines by high-throughput RNA sequencing. *Translational Oncology*, **2013**, 6, 546-53	4.9	22
154	A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. *Human Molecular Genetics*, **2013**, 22, 408-15	5.6	109
153	Molecular circuit involving KLK4 integrates androgen and mTOR signaling in prostate cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, E2572-81	11.5	50
152	Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression. *Human Molecular Genetics*, **2013**, 22, 2520-8	5.6	88
151	BMP2/BMP4 colorectal cancer susceptibility loci in northern and southern European populations. *Carcinogenesis*, **2013**, 34, 314-8	4.6	12
150	Genomic characterization of two large Alu-mediated rearrangements of the BRCA1 gene. *Journal of Human Genetics*, **2013**, 58, 78-83	4.3	22
149	Deregulation of PAX2 expression in renal cell tumours: mechanisms and potential use in differential diagnosis. *Journal of Cellular and Molecular Medicine*, **2013**, 17, 1048-58	5.6	13
148	Hyperdiploidy with 58-66 chromosomes in childhood B-acute lymphoblastic leukemia is highly curable: 58951 CLG-EORTC results. *Blood*, **2013**, 121, 2415-23	2.2	46
147	Altered expression of MGMT in high-grade gliomas results from the combined effect of epigenetic and genetic aberrations. *PLoS ONE*, **2013**, 8, e58206	3.7	27
146	Assessment of fusion gene status in sarcomas using a custom made fusion gene microarray. *PLoS ONE*, **2013**, 8, e70649	3.7	2
145	Carcinogenic ability of possibly through oncogenic mutation of gene **2013**, 2013,		11
144	Variability of the paracrine-induced osteoclastogenesis by human breast cancer cell lines. *Journal of Cellular Biochemistry*, **2012**, 113, 1069-79	4.7	8
143	FLI1 is a novel ETS transcription factor involved in gene fusions in prostate cancer. *Genes Chromosomes and Cancer*, **2012**, 51, 240-9	5	65
142	EGFR exon mutation distribution and outcome in non-small-cell lung cancer: a Portuguese retrospective study. *Tumor Biology*, **2012**, 33, 2061-8	2.9	24
141	FOXE1 polymorphisms are associated with familial and sporadic nonmedullary thyroid cancer susceptibility. *Clinical Endocrinology*, **2012**, 77, 926-33	3.4	49
140	Molecular subtyping of primary prostate cancer reveals specific and shared target genes of different ETS rearrangements. *Neoplasia*, **2012**, 14, 600-11	6.4	52
139	Portuguese c.156_157insAlu BRCA2 founder mutation: gastrointestinal and tongue neoplasias may be part of the phenotype. *Familial Cancer*, **2012**, 11, 657-60	3	9

138	12q amplification defines a subtype of extraskeletal osteosarcoma with good prognosis that is the soft tissue homologue of parosteal osteosarcoma. *Cancer Genetics*, **2012**, 205, 332-6	2.3	13
137	Li-Fraumeni-like syndrome associated with a large BRCA1 intragenic deletion. *BMC Cancer*, **2012**, 12, 237	4.8	22
136	Genetic and clinical characterization of 45 acute leukemia patients with MLL gene rearrangements from a single institution. *Molecular Oncology*, **2012**, 6, 553-64	7.9	14
135	Cernunnos influences human immunoglobulin class switch recombination and may be associated with B cell lymphomagenesis. *Journal of Experimental Medicine*, **2012**, 209, 291-305	16.6	34
134	Desmoplastic small round cell tumor: diagnosis by fine-needle aspiration cytology. *Acta Cytologica*, **2012**, 56, 576-80	3	13
133	Potential downstream target genes of aberrant ETS transcription factors are differentially affected in Ewing's sarcoma and prostate carcinoma. *PLoS ONE*, **2012**, 7, e49819	3.7	18
132	Prognostic Impact of High Hematogones in Acute Myeloid Leukemia. *Blood*, **2012**, 120, 1435-1435	2.2	
131	Cysteine-rich secretory protein-3 (CRISP3) is strongly up-regulated in prostate carcinomas with the TMPRSS2-ERG fusion gene. *PLoS ONE*, **2011**, 6, e22317	3.7	33
130	Cytogenetic analysis of tumor clonality. *Advances in Cancer Research*, **2011**, 112, 127-49	5.9	17
129	Comparison of methodologies for KRAS mutation detection in metastatic colorectal cancer. *Cancer Genetics*, **2011**, 204, 439-46	2.3	35
128	TCF21 and PCDH17 methylation: An innovative panel of biomarkers for a simultaneous detection of urological cancers. *Epigenetics*, **2011**, 6, 1120-30	5.7	88
127	Intraepidermal epidermotropic metastatic melanoma: a clinical and histopathological mimicker of melanoma in situ occurring in multiplicity. *Journal of Cutaneous Pathology*, **2011**, 38, 514-20	1.7	11
126	International distribution and age estimation of the Portuguese BRCA2 c.156_157insAlu founder mutation. *Breast Cancer Research and Treatment*, **2011**, 127, 671-9	4.4	21
125	Endometrial endometrioid adenocarcinoma associated with primitive neuroectodermal tumour of the uterus: a poor prognostic subtype of uterine tumours. *Medical Oncology*, **2011**, 28, 1488-94	3.7	5
124	Acute megakaryoblastic leukemia with a four-way variant translocation originating the RBM15-MKL1 fusion gene. *Pediatric Blood and Cancer*, **2011**, 56, 846-9	3	11
123	Relative 8q gain predicts disease-specific survival irrespective of the TMPRSS2-ERG fusion status in diagnostic biopsies of prostate cancer. *Genes Chromosomes and Cancer*, **2011**, 50, 662-71	5	22
122	MLL-SEPTIN gene fusions in hematological malignancies. *Biological Chemistry*, **2011**, 392, 713-24	4.5	39
121	A novel exonic rearrangement affecting MLH1 and the contiguous LRRFIP2 is a founder mutation in Portuguese Lynch syndrome families. *Genetics in Medicine*, **2011**, 13, 895-902	8.1	17

120	Three epigenetic biomarkers, GDF15, TMEFF2, and VIM, accurately predict bladder cancer from DNA-based analyses of urine samples. *Clinical Cancer Research*, **2010**, 16, 5842-51	12.9	134
119	Epigenetic regulation of Wnt signaling pathway in urological cancer. *Epigenetics*, **2010**, 5, 343-51	5.7	33
118	Tumors of the Breast **2010**, 493-516		
117	Tumors of the Male Genital Organs **2010**, 557-575		
116	Distinct high resolution genome profiles of early onset and late onset colorectal cancer integrated with gene expression data identify candidate susceptibility loci. *Molecular Cancer*, **2010**, 9, 100	42.1	65
115	Genomic changes in chromosomes 10, 16, and X in malignant peripheral nerve sheath tumors identify a high-risk patient group. *Journal of Clinical Oncology*, **2010**, 28, 1573-82	2.2	47
114	Detailed analysis of expression and promoter methylation status of apoptosis-related genes in prostate cancer. *Apoptosis: an International Journal on Programmed Cell Death*, **2010**, 15, 956-65	5.4	35
113	Promoter methylation and large intragenic rearrangements of DPYD are not implicated in severe toxicity to 5-fluorouracil-based chemotherapy in gastrointestinal cancer patients. *BMC Cancer*, **2010**, 10, 470	4.8	16
112	A novel spliced fusion of MLL with CT45A2 in a pediatric biphenotypic acute leukemia. *BMC Cancer*, **2010**, 10, 518	4.8	9
111	Colorectal carcinomas with microsatellite instability display a different pattern of target gene mutations according to large bowel site of origin. *BMC Cancer*, **2010**, 10, 587	4.8	27
110	Chromosome copy number changes carry prognostic information independent of KIT/PDGFRA point mutations in gastrointestinal stromal tumors. *BMC Medicine*, **2010**, 8, 26	11.4	10
109	Coexistence of alternative MLL-SEPT9 fusion transcripts in an acute myeloid leukemia with t(11;17)(q23;q25). *Cancer Genetics and Cytogenetics*, **2010**, 197, 60-4		12
108	Hereditary gastrointestinal stromal tumors sharing the KIT Exon 17 germline mutation p.Asp820Tyr develop through different cytogenetic progression pathways. *Genes Chromosomes and Cancer*, **2010**, 49, 91-8	5	16
107	Genotypic and phenotypic classification of cancer: How should the impact of the two diagnostic approaches best be balanced?. *Genes Chromosomes and Cancer*, **2010**, 49, 763-74	5	5
106	Feasibility of differential diagnosis of kidney tumors by comparative genomic hybridization of fine needle aspiration biopsies. *Genes Chromosomes and Cancer*, **2010**, 49, 935-47	5	38
105	Expression pattern of the septin gene family in acute myeloid leukemias with and without MLL-SEPT fusion genes. *Leukemia Research*, **2010**, 34, 615-21	2.7	17
104	Both SEPT2 and MLL are down-regulated in MLL-SEPT2 therapy-related myeloid neoplasia. *BMC Cancer*, **2009**, 9, 147	4.8	7
103	Molecular diagnosis of the Portuguese founder mutation BRCA2 c.156_157insAlu. *Breast Cancer Research and Treatment*, **2009**, 117, 215-7	4.4	8

102	The c.156_157insAlu BRCA2 rearrangement accounts for more than one-fourth of deleterious BRCA mutations in northern/central Portugal. *Breast Cancer Research and Treatment*, **2009**, 114, 31-8	4.4	46
101	Haplotype and quantitative transcript analyses of Portuguese breast/ovarian cancer families with the BRCA1 R71G founder mutation of Galician origin. *Familial Cancer*, **2009**, 8, 203-8	3	9
100	TP53 germline mutations in Portugal and genetic modifiers of age at cancer onset. *Familial Cancer*, **2009**, 8, 383-90	3	12
99	CSF1R copy number changes, point mutations, and RNA and protein overexpression in renal cell carcinomas. *Modern Pathology*, **2009**, 22, 744-52	9.8	19
98	Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. *British Journal of Cancer*, **2009**, 100, 487-93	8.7	124
97	Altered expression of key cell cycle regulators in renal cell carcinoma associated with Xp11.2 translocation. *Pathology Research and Practice*, **2009**, 205, 466-72	3.4	7
96	Mitochondrial genome alterations in rectal and sigmoid carcinomas. *Cancer Letters*, **2009**, 280, 38-43	9.9	18
95	A universal assay for detection of oncogenic fusion transcripts by oligo microarray analysis. *Molecular Cancer*, **2009**, 8, 5	42.1	23
94	Heterogeneous genetic profiles in soft tissue myoepitheliomas. *Modern Pathology*, **2008**, 21, 1311-9	9.8	42
93	Array CGH and gene-expression profiling reveals distinct genomic instability patterns associated with DNA repair and cell-cycle checkpoint pathways in Ewing's sarcoma. *Oncogene*, **2008**, 27, 2084-90	9.2	58
92	Conventional and molecular cytogenetics of human non-medullary thyroid carcinoma: characterization of eight cell line models and review of the literature on clinical samples. *BMC Cancer*, **2008**, 8, 371	4.8	30
91	A novel MLL-SEPT2 fusion variant in therapy-related myelodysplastic syndrome. *Cancer Genetics and Cytogenetics*, **2008**, 185, 62-4		4
90	Cryptic chromosome rearrangement resulting in SYT-SSX2 fusion gene in a monophasic synovial sarcoma. *Cancer Genetics and Cytogenetics*, **2008**, 187, 45-9		11
89	Molecular characterization of the MLL-SEPT6 fusion gene in acute myeloid leukemia: identification of novel fusion transcripts and cloning of genomic breakpoint junctions. *Haematologica*, **2008**, 93, 1076-80	6.6	13
88	Chromosome mechanisms giving rise to the TMPRSS2-ERG fusion oncogene in prostate cancer and HGPIN lesions. *American Journal of Surgical Pathology*, **2008**, 32, 642-4; author reply 644	6.7	19
87	Quantitative hypermethylation of a small panel of genes augments the diagnostic accuracy in fine-needle aspirate washings of breast lesions. *Breast Cancer Research and Treatment*, **2008**, 109, 27-34	4.4	46
86	Genetic diagnosis of alveolar rhabdomyosarcoma in the bone marrow of a patient without evidence of primary tumor. *Pediatric Blood and Cancer*, **2008**, 51, 554-7	3	8
85	Array-Based Comparative Genomic Hybridization in Prostate Cancer: Research and Clinical Applications **2008**, 415-429		

84	Overexpression of the mitotic checkpoint genes BUB1 and BUBR1 is associated with genomic complexity in clear cell kidney carcinomas. *Cellular Oncology*, **2008**, 30, 389-95		22
83	Quantitative promoter methylation analysis of multiple cancer-related genes in renal cell tumors. *BMC Cancer*, **2007**, 7, 133	4.8	50
82	Molecular characterization of a rare MLL-AF4 (MLL-AFF1) fusion rearrangement in infant leukemia. *Cancer Genetics and Cytogenetics*, **2007**, 178, 61-4		2
81	Relative copy number gain of MYC in diagnostic needle biopsies is an independent prognostic factor for prostate cancer patients. *European Urology*, **2007**, 52, 116-25	10.2	43
80	Reply to AnnaMaria Cianciulli, Roberta Merola and Costantino Leonardo Letter to the Editor re: Franclim R. Ribeiro, Rui Henrique, Ana T. Martins, Carmen Jer imo and Manuel R. Teixeira. Relative Copy Number Gain of MYC in Diagnostic Needle Biopsies is an Independent Prognostic Factor for Prostate Cancer Patients. Eur Urol 2007;52:116 25. *European Urology*, **2007**, 52, 1539-1540	10.2	
79	Intratumor genomic heterogeneity in breast cancer with clonal divergence between primary carcinomas and lymph node metastases. *Breast Cancer Research and Treatment*, **2007**, 102, 143-55	4.4	135
78	Expression changes of the MAD mitotic checkpoint gene family in renal cell carcinomas characterized by numerical chromosome changes. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2007**, 450, 379-85	5.1	15
77	High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients. *Clinical Cancer Research*, **2007**, 13, 6122-9	12.9	109
76	Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer. *Journal of Molecular Medicine*, **2006**, 84, 911-8	5.5	47
75	Chromosome analysis and molecular cytogenetic investigations of an epithelioid hemangioendothelioma. *Cancer Genetics and Cytogenetics*, **2006**, 169, 164-8		14
74	The order of genetic events associated with colorectal cancer progression inferred from meta-analysis of copy number changes. *Genes Chromosomes and Cancer*, **2006**, 45, 31-41	5	131
73	Statistical dissection of genetic pathways involved in prostate carcinogenesis. *Genes Chromosomes and Cancer*, **2006**, 45, 154-63	5	40
72	Epigenetic heterogeneity of high-grade prostatic intraepithelial neoplasia: clues for clonal progression in prostate carcinogenesis. *Molecular Cancer Research*, **2006**, 4, 1-8	6.6	82
71	8q gain is an independent predictor of poor survival in diagnostic needle biopsies from prostate cancer suspects. *Clinical Cancer Research*, **2006**, 12, 3961-70	12.9	57
70	TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. *Neoplasia*, **2006**, 8, 826-32	6.4	191
69	Comparison of chromosomal and array-based comparative genomic hybridization for the detection of genomic imbalances in primary prostate carcinomas. *Molecular Cancer*, **2006**, 5, 33	42.1	17
68	ADAMTS1, CRABP1, and NR3C1 identified as epigenetically deregulated genes in colorectal tumorigenesis. *Analytical Cellular Pathology*, **2006**, 28, 259-72	3.4	73
67	MSH6 germline mutations in early-onset colorectal cancer patients without family history of the disease. *British Journal of Cancer*, **2006**, 95, 752-6	8.7	18

66	SEPT2 is a new fusion partner of MLL in acute myeloid leukemia with t(2;11)(q37;q23). *Oncogene*, **2006**, 25, 6147-52	9.2	39
65	Recurrent fusion oncogenes in carcinomas. *Critical Reviews in Oncogenesis*, **2006**, 12, 257-71	1.3	38
64	The loss of NKX3.1 expression in testicular--and prostate--cancers is not caused by promoter hypermethylation. *Molecular Cancer*, **2005**, 4, 8	42.1	5
63	Multimodal genetic diagnosis of solid variant alveolar rhabdomyosarcoma. *Cancer Genetics and Cytogenetics*, **2005**, 163, 138-43		13
62	Multiple numerical chromosome aberrations in cancer: what are their causes and what are their consequences?. *Seminars in Cancer Biology*, **2005**, 15, 3-12	12.7	31
61	No significant role for beta tubulin mutations and mismatch repair defects in ovarian cancer resistance to paclitaxel/cisplatin. *BMC Cancer*, **2005**, 5, 101	4.8	29
60	Adenomas and follicular carcinomas of the thyroid display two major patterns of chromosomal changes. *Journal of Pathology*, **2005**, 206, 305-11	9.4	33
59	TP53 mutations are associated with a particular pattern of genomic imbalances in breast carcinomas. *Journal of Pathology*, **2005**, 207, 14-9	9.4	7
58	SMARCB1/INI1 tumor suppressor gene is frequently inactivated in epithelioid sarcomas. *Cancer Research*, **2005**, 65, 4012-9	10.1	268
57	Frequent 14-3-3 sigma promoter methylation in benign and malignant prostate lesions. *DNA and Cell Biology*, **2005**, 24, 264-9	3.6	56
56	MT1G hypermethylation is associated with higher tumor stage in prostate cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2005**, 14, 1274-8	4	58
55	Quantitative RARbeta2 hypermethylation: a promising prostate cancer marker. *Clinical Cancer Research*, **2004**, 10, 4010-4	12.9	108
54	A quantitative promoter methylation profile of prostate cancer. *Clinical Cancer Research*, **2004**, 10, 8472-8	12.9	209
53	Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status. *Human Molecular Genetics*, **2004**, 13, 2303-11	5.6	102
52	Mutations in exon 14 of dihydropyrimidine dehydrogenase and 5-Fluorouracil toxicity in Portuguese colorectal cancer patients. *Genetics in Medicine*, **2004**, 6, 102-7	8.1	24
51	Aberrant cellular retinol binding protein 1 (CRBP1) gene expression and promoter methylation in prostate cancer. *Journal of Clinical Pathology*, **2004**, 57, 872-6	3.9	39
50	Genome signatures of colon carcinoma cell lines. *Cancer Genetics and Cytogenetics*, **2004**, 155, 119-31		51
49	Cyclin D1 A870G polymorphism and amplification in laryngeal squamous cell carcinoma: implications of tumor localization and tobacco exposure. *Cancer Detection and Prevention*, **2004**, 28, 237-43		35

48	Genomic aberrations in carcinomas of the uterine corpus. *Genes Chromosomes and Cancer*, **2004**, 40, 229-46	5	57
47	Molecular cytogenetic characterization of proximal-type epithelioid sarcoma. *Genes Chromosomes and Cancer*, **2004**, 41, 283-90	5	59
46	Genomic analysis of prostate carcinoma specimens obtained via ultrasound-guided needle biopsy may be of use in preoperative decision-making. *Cancer*, **2004**, 101, 1786-93	6.4	25
45	Highly sensitive detection of the MGB1 transcript (mammaglobin) in the peripheral blood of breast cancer patients. *International Journal of Cancer*, **2004**, 108, 592-5	7.5	25
44	Genome characteristics of primary carcinomas, local recurrences, carcinomatoses, and liver metastases from colorectal cancer patients. *Molecular Cancer*, **2004**, 3, 6	42.1	30
43	Cytogenetic and molecular genetic analyses of endometrial stromal sarcoma: nonrandom involvement of chromosome arms 6p and 7p and confirmation of JAZF1/JJAZ1 gene fusion in t(7;17). *Cancer Genetics and Cytogenetics*, **2003**, 144, 119-24		82
42	Karyotypic divergence and convergence in two synchronous lung metastases of a clear cell sarcoma of tendons and aponeuroses with t(12;22)(q13;q12) and type 1 EWS/ATF1. *Cancer Genetics and Cytogenetics*, **2003**, 145, 121-5		3
41	Genetic profiling of colorectal cancer liver metastases by combined comparative genomic hybridization and G-banding analysis. *Genes Chromosomes and Cancer*, **2003**, 36, 189-97	5	32
40	Cytogenetic characterization of tumors of the vulva and vagina. *Genes Chromosomes and Cancer*, **2003**, 38, 137-48	5	23
39	Multicentric mammary carcinoma: evidence of monoclonal proliferation. *Cancer*, **2003**, 97, 715-7; author reply 717	6.4	2
38	8q24 Copy number gains and expression of the c-myc mRNA stabilizing protein CRD-BP in primary breast carcinomas. *International Journal of Cancer*, **2003**, 104, 54-9	7.5	49
37	Frequency of NUP98-NSD1 fusion transcript in childhood acute myeloid leukaemia. *Leukemia*, **2003**, 17, 2244-7	10.7	52
36	Telomerase activity and genetic alterations in primary breast carcinomas. *Neoplasia*, **2003**, 5, 170-8	6.4	7
35	Detection of gene promoter hypermethylation in fine needle washings from breast lesions. *Clinical Cancer Research*, **2003**, 9, 3413-7	12.9	46
34	Genome profiling of breast cancer cells selected against in vitro shows copy number changes. *Genes Chromosomes and Cancer*, **2002**, 33, 304-9	5	15
33	Cytogenetic clues to breast carcinogenesis. *Genes Chromosomes and Cancer*, **2002**, 33, 1-16	5	55
32	Characterization of supernumerary rings and giant marker chromosomes in well-differentiated lipomatous tumors by a combination of G-banding, CGH, M-FISH, and chromosome- and locus-specific FISH. *Cytogenetic and Genome Research*, **2002**, 97, 13-9	1.9	39
31	Combined classical and molecular cytogenetic analysis of cancer. *European Journal of Cancer*, **2002**, 38, 1580-4	7.5	27

30	Complete cytogenetic characterization of the human breast cancer cell line MA11 combining G-banding, comparative genomic hybridization, multicolor fluorescence in situ hybridization, RxFISH, and chromosome-specific painting. *Cancer Genetics and Cytogenetics*, **2001**, 131, 25-30		21
29	Evaluation of breast cancer polyclonality by combined chromosome banding and comparative genomic hybridization analysis. *Neoplasia*, **2001**, 3, 204-14	6.4	29
28	High frequency of clonal chromosome abnormalities in prostatic neoplasms sampled by prostatectomy or ultrasound-guided needle biopsy **2000**, 28, 211-219		10
27	Detailed genome-wide screening for inter- and intrachromosomal abnormalities by sequential G-banding and RxFISH color banding of the same metaphase cells. *Cancer Genetics and Cytogenetics* , **2000**, 119, 94-101		27
26	Acute myeloid leukemia with inv(8)(p11q13). *Leukemia and Lymphoma*, **2000**, 39, 651-6	1.9	19
25	Cytogenetic Approaches to Breast Cancer **1999**, 373-388		
24	Combined RxFISH/G-banding allows refined karyotyping of solid tumors. *Human Genetics*, **1999**, 104, 370-5	6.3	24
23	Karyotypic findings in tumors of the vulva and vagina. *Cancer Genetics and Cytogenetics*, **1999**, 111, 87-91		20
22	Karyotypic evolution in breast carcinomas with i(1)(q10) and der(1;16)(q10;p10) as the primary chromosome abnormality. *Cancer Genetics and Cytogenetics*, **1999**, 113, 156-61		25
21	Cross-species color banding characterization of chromosomal rearrangements in leukemias with incomplete G-band karyotypes **1999**, 26, 13-19		25
20	Translocation (3;3)(p14;q29) as the primary chromosome abnormality in a peritoneal mesothelioma. *Cancer Genetics and Cytogenetics*, **1998**, 103, 73-5		2
19	Cytogenetic comparison of primary tumors and lymph node metastases in breast cancer patients **1998**, 22, 122-129		38
18	Cytogenetic analysis shows that carcinosarcomas of the breast are of monoclonal origin. *Genes Chromosomes and Cancer*, **1998**, 22, 145-151	5	50
17	Chromosome banding analysis of gynecomastias and breast carcinomas in men. *Genes Chromosomes and Cancer*, **1998**, 23, 16-20	5	27
16	Cytogenetic analysis of several pseudomyxoma peritonei lesions originating from a mucinous cystadenoma of the appendix. *Cancer Genetics and Cytogenetics*, **1997**, 93, 157-9		14
15	Cytogenetic polyclonality in tumors of the breast. *Cancer Genetics and Cytogenetics*, **1997**, 95, 16-9		48
14	Fluorescence in situ hybridization of old G-banded and mounted chromosome preparations. *Cancer Genetics and Cytogenetics*, **1997**, 98, 9-15		6
13	Discrimination between multicentric and multifocal breast carcinoma by cytogenetic investigation of macroscopically distinct ipsilateral lesions. *Genes Chromosomes and Cancer*, **1997**, 18, 170-4	5	34

12	Cytogenetic abnormalities in an in situ ductal carcinoma and five prophylactically removed breasts from members of a family with hereditary breast cancer. *Breast Cancer Research and Treatment*, **1996**, 38, 177-82	4.4	26
11	Chromosome abnormalities in bilateral breast carcinomas. Cytogenetic evaluation of the clonal origin of multiple primary tumors. *Cancer*, **1995**, 76, 250-8	6.4	69
10	Chromosome abnormalities in benign hyperproliferative disorders of epithelial and stromal breast tissue. *International Journal of Cancer*, **1995**, 60, 49-53	7.5	85
9	Clonal heterogeneity in breast cancer: karyotypic comparisons of multiple intra- and extra-tumorous samples from 3 patients. *International Journal of Cancer*, **1995**, 63, 63-8	7.5	72
8	Karyotypic changes in phyllodes tumors of the breast. *Cancer Genetics and Cytogenetics*, **1994**, 78, 200-6		24
7	Cytogenetic analysis of multifocal breast carcinomas: detection of karyotypically unrelated clones as well as clonal similarities between tumour foci. *British Journal of Cancer*, **1994**, 70, 922-7	8.7	51
6	Polygenic Risk Modelling for Prediction of Epithelial Ovarian Cancer Risk		1
5	A genetic risk score to guide age-specific, personalized prostate cancer screening		1
4	Polygenic hazard score is associated with prostate cancer in multi-ethnic populations		1
3	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses		2
2	Tumors of the breast426-446		
1	Tumors of the male genital organs481-496		